VEGFA and age-related macular degeneration: It did not examine the occurrence of treatment gaps or discontinuation, the underlying causes of sustained poor vision or considerable vision loss, or the potential association between the frequency of intravitreal anti-VEGF injections, patient baseline characteristics, and BCVA outcomes in neovascular age-related macular degeneration.